Oxford Biomedica PLC

Director's Dealing • Jun 10, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7123B

Oxford Biomedica PLC

10 June 2019

PDMR Dealings / Market Share sale

Oxford, UK - 10 June 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 June 2019, that Dr. Jason Slingsby, Chief Business Officer of the Group, exercised 12,014 options at 274.7p each and sold all of the resulting shares at 760p. Following this transaction he holds 91,822 options and no shares in the Company.

The issued share capital of the Group is 76,738,168 ordinary 50p shares.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares purchased.

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Jason Slingsby

2.

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
£2.747	12,014

e)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

12,014

£2.747

£33,002.46

f)

Date of the transaction

2019-06-07

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Jason Slingsby

2.

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford BioMedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 50 pence each

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Disposal

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

Price(s)	Volume(s)
£7.60	12,014

e)

Aggregated information

-    Aggregate volume

-    Price

-    Aggregated total

12,014

£7.60

£91,306.40

f)

Date of the transaction

2019-06-07

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Stuart Paynter, Company Secretary	Tel: +44 (0)1865 783 000

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHBXGDLXXBBGCG